AzTrials
AzTrials

HIV InfectionsNCT00742898

Evaluation of Opt-Out Rapid HIV Testing in the Emergency Department

A study testing Non-targeted opt-out rapid HIV screening in people with HIV Infections, run by Denver Health and Hospital Authority at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the clinical effectiveness of performing opt-out rapid HIV screening in an urban, inner-city emergency department, as well as to evaluate its clinical efficiency, cost effectiveness, and patient and staff satisfaction. Read more about this study

Who is it for?
Ages 16 years and older
Conditions the study is for
HIV Infections
What is being tested?
Non-targeted opt-out rapid HIV screening
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120,000 participants
Where
1 siteUnited States
Study dates
Apr 2007to Apr 2009
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • 16 years or older
  • Emergency department patients

Who cannot join

  • <16 years
  • Unable to provide consent (e.g., intoxicated, altered mental status)
  • Critical illness
  • Prisoners or detainees
  • Already known to be infected with HIV
  • Victims of sexual assault
  • Occupational exposures

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Denver Health Medical Center

    Denver, Colorado, 80204

Other trials in United States

About this study

Official title: Non-targeted Opt-out Rapid HIV Screening in the Emergency Department: a Controlled Clinical Trial

The purpose of this study is to evaluate the clinical effectiveness of performing opt-out rapid HIV screening in an urban, inner-city emergency department, as well as to evaluate its clinical efficiency, cost effectiveness, and patient and staff satisfaction.

Read the detailed description

An estimated 40,000 new HIV infections occur annually in the United States. Although significant effort has been devoted to improving identification of patients with undiagnosed HIV infection, this rate has changed very little in the last decade and new infections appear to be increasing most in non-traditional risk groups, including racial and ethnic minorities. Most persons infected with HIV still do not get tested until late in their disease courses, primarily due to its long asymptomatic period and their relatively poor access to routine medical care. Over 100 million people visit emergency departments (EDs) annually, and the ED commonly serves as a patient's only source for medical care, and thus the only potential opportunity to receive HIV counseling, testing, and referral (CTR). Also, patients who are most likely to use the ED as their only source of care are often those for whom the HIV epidemic is spreading most. The primary objective of the proposed research is to demonstrate clinical effectiveness, clinical efficiency, cost effectiveness, and patient-staff satisfaction with performing routine voluntary opt-out rapid HIV CTR in a high-volume urban ED, when compared to a targeted rapid HIV CTR program in the same setting. The primary hypothesis of the proposed investigations is that opt-out rapid HIV CTR is associated with a higher rate of overall testing, identification of patients infected with HIV, identification of patients infected with HIV earlier in their disease courses, and successful linkage into medical and preventative care for those patients who test positive for HIV infection. The secondary hypotheses are that opt-out rapid HIV CTR: (1) is not associated with increased ED processes of care, defined by patient waiting times, length of stays, the proportion of patients who leave before completing their evaluations, and an overcrowding index; and (2) is cost-effective. The tertiary hypotheses are that opt-out rapid HIV CTR is associated with a higher level of patient and ED staff satisfaction. To address these hypotheses, we will perform a prospective quasi-experimental equivalent time-samples clinical trial in which consecutive patients who present to the ED during interventional periods will be offered opt-out rapid HIV CTR as part of their visits, and during the control periods, patients will be targeted by physicians for rapid HIV CTR using a previously developed and validated CTR model. The results obtained from this study will improve our understanding of how best to identify patients with HIV infection in ED, and whether opt-out rapid HIV CTR is an effective means to achieve the CDC's goals of identifying more asymptomatic HIV-infected patients earlier in their disease courses.

Conditions
HIV Infections
Being tested
Non-targeted opt-out rapid HIV screening
Keywords
Quasi-experimental design, Non-targeted opt-out rapid HIV screening, Diagnostic rapid HIV testing, Emergency department, Effectiveness, Efficiency, Health services research, Program evaluation, Effectiveness and efficiency of non-targeted rapid HIV screening in the ED
Medical subject headings
HIV Infections, Emergencies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Non-targeted opt-out rapid HIV screeningOther

    Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing

Study groups in NCT00742898
Study groupRoleWhat they receive
1ExperimentalNon-targeted opt-out rapid HIV screening fully integrated into an urban, inner-city ED.
Receives: Other: Non-targeted opt-out rapid HIV screening
2Active comparatorDiagnostic rapid HIV testing fully integrated into an urban, inner-city ED.
Receives: Other: Non-targeted opt-out rapid HIV screening

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. HIV seropositivity

    Measured: Immediate

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Aug 2008 (estimated)
  2. Study startApr 2007
  3. Primary completionApr 2009
  4. Study completionApr 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Non-randomised
Intervention model
Factorial
Masking
None (open label)
Enrolment
120,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00742898
Sponsor's protocol ID
06-0820
Other IDs
U18PS000314
Status last verified
Sep 2009
First submitted
10 Jan 2008
Last updated
15 Sep 2009
Results posted
No
Data monitoring committee
No

Publications

  • Haukoos JS, Hopkins E, Byyny RL, Conroy AA, Silverman M, Eisert S, Thrun M, Wilson M, Boyett B, Heffelfinger JD; Denver ED HIV Opt-Out Study Group. Design and implementation of a controlled clinical trial to evaluate the effectiveness and efficiency of routine opt-out rapid human immunodeficiency virus screening in the emergency department. Acad Emerg Med. 2009 Aug;16(8):800-8. doi: 10.1111/j.1553-2712.2009.00477.x.

    PubMed 19673717

Questions about this trial

What is this clinical trial studying?

A study testing Non-targeted opt-out rapid HIV screening in people with HIV Infections, run by Denver Health and Hospital Authority at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Sep 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HIV seropositivity (time frame: Immediate). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00742898, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2009.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in